Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 13676 | 3.46 |
09:34 ET | 24314 | 3.5 |
09:36 ET | 1000 | 3.505 |
09:38 ET | 9632 | 3.53 |
09:39 ET | 8740 | 3.526 |
09:41 ET | 5179 | 3.52 |
09:43 ET | 5977 | 3.5 |
09:50 ET | 1700 | 3.47 |
09:52 ET | 1100 | 3.46 |
09:54 ET | 3500 | 3.4599 |
09:56 ET | 500 | 3.45 |
09:57 ET | 3549 | 3.46 |
09:59 ET | 7700 | 3.45 |
10:01 ET | 453 | 3.4654 |
10:03 ET | 1500 | 3.455 |
10:06 ET | 1100 | 3.45 |
10:08 ET | 5168 | 3.435 |
10:10 ET | 9326 | 3.41 |
10:14 ET | 4307 | 3.405 |
10:15 ET | 4700 | 3.4199 |
10:17 ET | 1500 | 3.435 |
10:19 ET | 4204 | 3.435 |
10:21 ET | 1400 | 3.435 |
10:24 ET | 3400 | 3.435 |
10:26 ET | 1100 | 3.435 |
10:28 ET | 11144 | 3.445 |
10:30 ET | 19224 | 3.43 |
10:32 ET | 1400 | 3.4101 |
10:33 ET | 7950 | 3.42 |
10:35 ET | 1991 | 3.425 |
10:37 ET | 6969 | 3.425 |
10:39 ET | 1446 | 3.425 |
10:42 ET | 2127 | 3.405 |
10:44 ET | 6660 | 3.41 |
10:46 ET | 1500 | 3.415 |
10:48 ET | 2600 | 3.415 |
10:50 ET | 4200 | 3.42 |
10:51 ET | 1600 | 3.415 |
10:53 ET | 13494 | 3.4595 |
10:55 ET | 600 | 3.455 |
10:57 ET | 600 | 3.455 |
11:00 ET | 3100 | 3.455 |
11:02 ET | 1050 | 3.455 |
11:04 ET | 2800 | 3.45 |
11:06 ET | 3900 | 3.45 |
11:08 ET | 500 | 3.455 |
11:09 ET | 700 | 3.455 |
11:11 ET | 8934 | 3.45 |
11:13 ET | 15814 | 3.45 |
11:15 ET | 5852 | 3.455 |
11:18 ET | 1200 | 3.45 |
11:20 ET | 24559 | 3.455 |
11:22 ET | 600 | 3.455 |
11:24 ET | 1500 | 3.455 |
11:26 ET | 300 | 3.455 |
11:27 ET | 633 | 3.45 |
11:29 ET | 3110 | 3.455 |
11:31 ET | 2652 | 3.455 |
11:33 ET | 2400 | 3.46 |
11:36 ET | 3726 | 3.465 |
11:38 ET | 900 | 3.465 |
11:40 ET | 1445 | 3.465 |
11:42 ET | 700 | 3.465 |
11:44 ET | 100 | 3.47 |
11:45 ET | 1626 | 3.47 |
11:49 ET | 718 | 3.47 |
11:51 ET | 4626 | 3.475 |
11:54 ET | 1365 | 3.48 |
11:58 ET | 2000 | 3.495 |
12:00 ET | 426 | 3.485 |
12:02 ET | 300 | 3.486 |
12:03 ET | 26112 | 3.485 |
12:05 ET | 2456 | 3.485 |
12:07 ET | 2026 | 3.485 |
12:09 ET | 1632 | 3.48 |
12:12 ET | 2485 | 3.465 |
12:14 ET | 336 | 3.46 |
12:16 ET | 352 | 3.465 |
12:18 ET | 1100 | 3.465 |
12:20 ET | 1050 | 3.465 |
12:21 ET | 2350 | 3.475 |
12:23 ET | 5150 | 3.47 |
12:25 ET | 1600 | 3.465 |
12:27 ET | 200 | 3.465 |
12:30 ET | 100 | 3.465 |
12:32 ET | 1500 | 3.475 |
12:34 ET | 1226 | 3.465 |
12:36 ET | 1301 | 3.475 |
12:39 ET | 1190 | 3.465 |
12:41 ET | 1100 | 3.47 |
12:43 ET | 1919 | 3.465 |
12:45 ET | 200 | 3.465 |
12:48 ET | 700 | 3.47 |
12:54 ET | 2572 | 3.465 |
12:56 ET | 100 | 3.465 |
12:57 ET | 34554 | 3.465 |
12:59 ET | 3524 | 3.47 |
01:01 ET | 700 | 3.475 |
01:03 ET | 15136 | 3.49 |
01:06 ET | 3026 | 3.49 |
01:08 ET | 4300 | 3.49 |
01:10 ET | 4606 | 3.49 |
01:12 ET | 5200 | 3.495 |
01:14 ET | 1856 | 3.485 |
01:15 ET | 4996 | 3.48 |
01:17 ET | 3600 | 3.47 |
01:19 ET | 4754 | 3.475 |
01:21 ET | 678 | 3.46 |
01:24 ET | 7963 | 3.45 |
01:26 ET | 2144 | 3.45 |
01:28 ET | 10123 | 3.45 |
01:30 ET | 2400 | 3.455 |
01:32 ET | 426 | 3.455 |
01:33 ET | 21584 | 3.43 |
01:35 ET | 20359 | 3.45 |
01:37 ET | 800 | 3.455 |
01:39 ET | 5066 | 3.45 |
01:42 ET | 1250 | 3.455 |
01:44 ET | 3029 | 3.455 |
01:46 ET | 3478 | 3.465 |
01:48 ET | 800 | 3.465 |
01:53 ET | 4286 | 3.465 |
01:55 ET | 4107 | 3.47 |
01:57 ET | 8492 | 3.475 |
02:00 ET | 1100 | 3.475 |
02:02 ET | 1200 | 3.475 |
02:04 ET | 800 | 3.475 |
02:06 ET | 1126 | 3.475 |
02:08 ET | 400 | 3.475 |
02:09 ET | 3300 | 3.48 |
02:11 ET | 1240 | 3.485 |
02:13 ET | 6655 | 3.495 |
02:15 ET | 1700 | 3.4807 |
02:18 ET | 500 | 3.485 |
02:20 ET | 1626 | 3.495 |
02:22 ET | 700 | 3.495 |
02:24 ET | 6365 | 3.495 |
02:26 ET | 10195 | 3.4992 |
02:27 ET | 2284 | 3.505 |
02:29 ET | 1904 | 3.495 |
02:31 ET | 1100 | 3.495 |
02:33 ET | 1649 | 3.495 |
02:36 ET | 3326 | 3.495 |
02:38 ET | 1100 | 3.495 |
02:40 ET | 700 | 3.495 |
02:42 ET | 1000 | 3.495 |
02:44 ET | 2874 | 3.49 |
02:45 ET | 2211 | 3.495 |
02:47 ET | 1100 | 3.495 |
02:49 ET | 800 | 3.495 |
02:51 ET | 12752 | 3.5 |
02:54 ET | 3830 | 3.5 |
02:56 ET | 2000 | 3.5 |
02:58 ET | 9759 | 3.495 |
03:00 ET | 1220 | 3.5 |
03:02 ET | 8448 | 3.505 |
03:03 ET | 9585 | 3.505 |
03:05 ET | 2990 | 3.5 |
03:07 ET | 1660 | 3.5 |
03:09 ET | 4221 | 3.495 |
03:12 ET | 9900 | 3.495 |
03:14 ET | 11593 | 3.505 |
03:16 ET | 6626 | 3.515 |
03:18 ET | 9325 | 3.515 |
03:20 ET | 7506 | 3.515 |
03:21 ET | 8849 | 3.535 |
03:23 ET | 12809 | 3.53 |
03:25 ET | 6659 | 3.525 |
03:27 ET | 20369 | 3.55 |
03:30 ET | 10819 | 3.55 |
03:32 ET | 52990 | 3.555 |
03:34 ET | 25628 | 3.55 |
03:36 ET | 13847 | 3.525 |
03:38 ET | 4675 | 3.52 |
03:39 ET | 9129 | 3.51 |
03:41 ET | 14281 | 3.52 |
03:43 ET | 8748 | 3.515 |
03:45 ET | 6913 | 3.515 |
03:48 ET | 5600 | 3.515 |
03:50 ET | 6990 | 3.515 |
03:52 ET | 10309 | 3.545 |
03:54 ET | 34683 | 3.555 |
03:56 ET | 26333 | 3.57 |
03:57 ET | 19754 | 3.57 |
03:59 ET | 71168 | 3.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 550.1M | -11.5x | --- |
Stoke Therapeutics Inc | 704.1M | -5.6x | --- |
Immunome Inc | 725.6M | -2.2x | --- |
AnaptysBio Inc | 684.6M | -4.1x | --- |
SS Innovations International Inc | 725.6M | -31.0x | --- |
Praxis Precision Medicines Inc | 707.6M | -2.6x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $550.1M |
---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 152.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-0.31 |
Book Value | $0.44 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | 55.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.